Celgene vs. Deva: Pomalidomide Patent Injunction Secured in 22 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Celgene Corporation v. Deva Holding A.S. |
| Case Number | 2:25-cv-13687 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | July 23, 2025 – Aug 14, 2025 22 Days |
| Outcome | Plaintiff Win – Permanent Injunction |
| Patents at Issue | |
| Accused Products | Deva ANDA Product (Generic Pomalidomide) |
Case Overview
The Parties
⚖️ Plaintiff
Wholly owned subsidiary of Bristol Myers Squibb and NDA holder for Pomalyst® (pomalidomide), a blockbuster multiple myeloma treatment.
🛡️ Defendant
Turkish pharmaceutical manufacturer with active U.S. market ambitions, filed ANDA No. 22-0237 for generic pomalidomide.
The Patents at Issue
This landmark case involved three U.S. patents constituting the Patents-in-Suit, which form a layered IP fortress around pomalidomide:
- • U.S. Patent No. 8,828,427 — foundational pomalidomide composition and formulation claims
- • U.S. Patent No. 9,993,467 — method-of-treatment claims covering pomalidomide therapeutic use
- • U.S. Patent No. 10,555,939 — additional formulation or dosing-related claims protecting the Pomalyst® commercial product
Developing a generic drug?
Check if your generic formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
On August 14, 2025, the District of New Jersey entered a Consent Judgment and Permanent Injunction by stipulation of both parties. The injunction prohibits Deva — including all successors and assigns — from infringing U.S. Patent Nos. 8,828,427; 9,993,467; and 10,555,939 by making, using, selling, offering to sell, importing, or distributing the Deva ANDA Product until expiration of the Patents-in-Suit.
Legal Significance
The 22-day resolution is particularly notable. The consent judgment explicitly preserves Deva’s Paragraph IV certification rights and its research exemption protections. Equally significant: the judgment does not restrict FDA from ultimately approving ANDA No. 22-0237. This indicates a pragmatic capitulation tied to litigation cost-benefit analysis rather than a substantive concession on patent merits.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims covering composition, method-of-treatment, and formulation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Pomalidomide
This case highlights critical IP risks in pharmaceutical ANDA development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for generic pharma.
- View all related patents in this therapeutic area
- See key competitors in pomalidomide IP
- Understand ANDA litigation trends and strategies
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your generic pharmaceutical product.
- Input your generic product description or API
- AI identifies potentially blocking formulation/method patents
- Get actionable infringement risk assessment report
High Risk Area
Generic Pomalidomide Formulations
3 Patents-in-Suit
Layered IP protection around Pomalyst®
Strategy Insights
For ANDA filers & pharmaceutical innovators
✅ Key Takeaways
For Patent Attorneys & Litigators
Multi-patent portfolio strategies (composition, method-of-treatment, formulation) provide robust protection in Hatch-Waxman litigation.
Search related case law →Rapid consent judgments can be secured when generic challengers face strong patent positions and experienced counsel.
Explore precedents →For R&D Teams (Pharmaceutical)
Conduct thorough, layered FTO analysis covering all patent types before ANDA investment and development.
Start FTO analysis for my product →Monitor patent expiry timelines for all relevant patents, not just primary composition patents, for safe generic entry windows.
Try AI patent drafting →Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.